Beam Therapeutics 

Yahoo Finance • 9 months ago

Top 11 CRISPR Stocks To Invest In

In this article, we discuss the top 11 CRISPR stocks to invest in. If you want to skip our discussion of the gene editing industry, head directly to Top 5 CRISPR Stocks To Invest In. Genome editing refers to a set of technologies enabling... Full story

Yahoo Finance • 10 months ago

4 Cathie Wood Stocks Wall Street Thinks Will Skyrocket 83% to 168% in 2024

Cathie Wood crushed it in 2023. Her flagship Ark Innovation ETF(NYSEMKT: ARKK) soared nearly 67%. The Ark Next Generation Internet ETF(NYSEMKT: ARKW) performed even better with an impressive 97% gain. If analysts are right, Wood could hav... Full story

Yahoo Finance • 11 months ago

11 Most Promising Biotech Stocks to Buy According to Analysts

In this article, we will take a look at the 11 most promising biotech stocks to buy according to analysts. To skip our analysis of the recent trends, and market activity, you can go directly to see the 5 Most Promising Biotech Stocks to Bu... Full story

Yahoo Finance • last year

Is Beam Therapeutics Stock a Buy Now?

When it comes to gene-editing companies on the cutting edge, Beam Therapeutics (NASDAQ: BEAM) is keen to be one of the leaders. While it's a bit of a laggard in terms of its pipeline's maturity compared to a few of its competitors, few wou... Full story

Yahoo Finance • last year

Beam Therapeutics to Participate in 2023 Jefferies London Healthcare Conference

CAMBRIDGE, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, pla... Full story

Yahoo Finance • last year

Beam Therapeutics Reports Pipeline and Business Updates and Third Quarter 2023 Financial Results

Recent Portfolio Prioritization Focuses Business on Key Near-term Value Drivers and Long-term Growth of Precision Genetic Medicines Pipeline Lilly Acquires Beam’s Opt-In Rights to Verve Therapeutics’ Base Editing Cardiovascular Programs f... Full story

Yahoo Finance • last year

Beam Therapeutics Presents Preclinical Data Highlighting Utility and Durability of BEAM-301 to Correct a Glycogen Storage Disease Type I Deficiency Disease-Causing Mutation at ESGCT

Single Dose of BEAM-301 Restored Clinically Meaningful Endpoints in In Vivo Rodent Disease Models Out to at Least One Year Company Plans to Submit U.S. Investigational New Drug (IND) Application for BEAM-301 in the First Half of 2024 CAM... Full story

Yahoo Finance • last year

Beam Therapeutics Announces Portfolio Prioritization and Strategic Restructuring Focused on Potential Near-term Value Drivers and Long-term Growth of Precision Genetic Medicines Pipeline

Highest priority programs – BEAM-101 and ESCAPE for sickle cell disease and BEAM-302 for alpha-1 antitrypsin deficiency – expected to provide foundation for meaningful value creation Company to explore partnership opportunities for contin... Full story

Yahoo Finance • last year

Beam Therapeutics Presents Preclinical Data Highlighting Utility of BEAM-302 to Correct an Alpha-1 Antitrypsin (AAT) Deficiency Disease-Causing Mutation

CAMBRIDGE, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported new preclinical data demonstrating the abilit... Full story

Yahoo Finance • last year

Beam Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of BEAM-201 in Relapsed, Refractory T-ALL/T-LL

CAMBRIDGE, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that in August, the first patient was treate... Full story

Yahoo Finance • last year

Beam Therapeutics to Participate in Upcoming September Investor Conferences

CAMBRIDGE, Mass., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management plans to participate in fires... Full story

Yahoo Finance • last year

Again After a Significant Correction, Beam Therapeutics Looks Interesting Again

Biotechnology firm Beam Therapeutics Inc. does research in the field of gene therapies and genome editing. The stock price was cut in half the past year so now it may be more attractive to longer-term investors. In this daily bar chart of... Full story

Yahoo Finance • 2 years ago

Beam Therapeutics to Participate in Upcoming May Investor Conferences

CAMBRIDGE, Mass., May 17, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management plans to participate in firesi... Full story

Yahoo Finance • 2 years ago

Beam Therapeutics to Participate in RBC Capital Markets 2023 Global Healthcare Conference

CAMBRIDGE, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that Giuseppe Ciaramella, Ph.D., president of... Full story

Yahoo Finance • 2 years ago

3 Growth Stocks Cathie Wood Just Bought That Could Be Absolute Game-Changers

If there's one word you could use to describe the kinds of stocks that Cathie Wood buys, it would be "innovative." In fact, three of her ARK Invest exchange-traded funds (ETFs) include the word "innovation" in their names. Wood's flagship... Full story

Yahoo Finance • 2 years ago

Top 10 CRISPR Stocks To Buy

In this article, we discuss the top 10 CRISPR stocks to buy. If you want to see more stocks in this selection, check out Top 5 CRISPR Stocks To Buy. Molecular biology, genetics, and genomics are in a significant period in history where te... Full story

Yahoo Finance • 2 years ago

Beam Therapeutics to Participate in the Guggenheim 2023 Genomic Medicines and Rare Disease Day

CAMBRIDGE, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, wi... Full story

Yahoo Finance • 2 years ago

Beam Therapeutics Appoints Gopi Shanker, Ph.D., as Chief Scientific Officer

CAMBRIDGE, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that Gopi Shanker, Ph.D., has been appointed... Full story

Yahoo Finance • 2 years ago

Beam Therapeutics to Participate in the Barclays 2023 Global Healthcare Conference

CAMBRIDGE, Mass., March 15, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that Giuseppe Ciaramella, Ph.D., president o... Full story

Yahoo Finance • 2 years ago

Beam Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Reiterates Anticipated Milestones

Advancing Pipeline of Wholly Owned Base Editing Therapeutics with Four Development-stage Programs Expanding Investment in a Broad Portfolio of Potential New Programs Designed to Extend Reach of Base Editing Medicines North Carolina Manuf... Full story